Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients
- First Posted Date
- 2013-04-08
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT01825980
- Locations
- 🇺🇸
Novartis Investigative Site, San Antonio, Texas, United States
Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes
Phase 2
Withdrawn
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2013-04-04
- Last Posted Date
- 2014-04-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01824264
Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)
Phase 1
Completed
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2013-04-02
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT01822613
- Locations
- 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
🇺🇸University of Chicago Medical Center Dept of Onc, Chicago, Illinois, United States
🇺🇸Karmanos Cancer Institute Dept of Onc, Detroit, Michigan, United States
Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer
Phase 1
Terminated
- Conditions
- Non-Small Cell Lunch Cancer
- Interventions
- First Posted Date
- 2013-03-28
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 6
- Registration Number
- NCT01820325
- Locations
- 🇺🇸
Northwest Cancer Specialists Compass Oncology -BKM, Portland, Oregon, United States
🇪🇸Novartis Investigative Site, Madrid, Spain
🇺🇸Highlands Oncology Group, Fayetteville, Arkansas, United States
Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients
Phase 4
Terminated
- Conditions
- Aplastic Anemia
- Interventions
- First Posted Date
- 2013-03-26
- Last Posted Date
- 2019-08-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT01818726
- Locations
- 🇷🇺
Novartis Investigative Site, Moscow, Russian Federation
NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer
Phase 2
Completed
- Conditions
- HER2-positive Newly Diagnosed, Primary Breast Cancer
- Interventions
- First Posted Date
- 2013-03-22
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT01816594
- Locations
- 🇪🇸
Novartis Investigative Site, Madrid, Spain
Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy
Phase 2
Terminated
- Conditions
- Failed SSRI Over 12 Weeks at Appropriate DosesPatient Diagnosed With OCD and Resistant to SSRI Treatment
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-03-18
- Last Posted Date
- 2017-01-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT01813019
- Locations
- 🇨🇭
Novartis Investigative Site, Bern, Switzerland
Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: PlaceboDrug: LMF237 50/250 mgDrug: LMF237 50/500 mg
- First Posted Date
- 2013-03-14
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 171
- Registration Number
- NCT01811485
- Locations
- 🇯🇵
Novartis Investigative Site, Toshima-ku, Tokyo, Japan
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
Phase 2
Completed
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD)
- Interventions
- Drug: placebo
- First Posted Date
- 2013-03-14
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT01811472
- Locations
- 🇺🇸
Novartis Investigative Site, Richmond, Virginia, United States
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
Phase 3
Completed
- Conditions
- Moderate to Severe Nail Psoriasis
- Interventions
- Biological: SecukinumabBiological: Placebo
- First Posted Date
- 2013-03-08
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 198
- Registration Number
- NCT01807520
- Locations
- 🇬🇧
Novartis Investigative Site, Staffordshire, United Kingdom